Related Experiment Video

Updated: Dec 23, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer

Feiling Feng1, Qingbao Cheng1, Dadong Zhang2

  • 1Department of Biliary I, Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, P.R. China.

Oncology Reports
|April 24, 2020
PubMed

Insights

Personalized targeted therapy guided by deep sequencing improved outcomes for advanced biliary tract cancer (BTC) patients after non-radical resection. This approach showed longer progression-free survival and overall survival compared to conventional chemotherapy.

Area of Science:

  • Oncology
  • Genomics
  • Personalized Medicine

Background:

  • Targeted therapy offers effective cancer treatment based on genetic alterations.
  • Biliary tract cancer (BTC) is a challenging disease, especially after non-radical resection.
  • Identifying actionable mutations is crucial for guiding treatment decisions.

Purpose of the Study:

  • To evaluate the efficacy of personalized targeted therapy guided by targeted deep sequencing in advanced BTC patients with non-radical resection.
  • To compare outcomes between patients receiving targeted therapy and those undergoing conventional chemotherapy.

Main Methods:

  • Targeted deep sequencing was performed on 49 advanced BTC patients.
  • Biologic agents were recommended based on sequencing results.
  • A cohort of 32 patients with stage IV and R2 resection were divided into two groups: 21 received conventional chemotherapy (mGEMOX) and 11 received personalized targeted agents.

Main Results:

  • The genomic landscape revealed enriched alterations in the ERBB family and cell cycle pathways.
  • Personalized targeted therapy group (11 patients) showed median progression-free survival (PFS) of 4.5 months and median overall survival (OS) of 12.9 months, with a disease control rate (DCR) of 63.6%.
  • Conventional chemotherapy group (21 patients) had median PFS of 1.5 months, median OS of 4.1 months, and DCR of 33.3%.
  • Higher grade toxicity (>2) was observed in 36.4% of the targeted therapy group versus 19.0% in the conventional chemotherapy group.

Conclusions:

  • Targeted deep sequencing can guide personalized targeted therapy for advanced BTC patients.
  • This approach may offer significant clinical benefits for patients undergoing non-radical resection.
  • Personalized therapy demonstrated improved survival outcomes and disease control compared to standard chemotherapy.
Keywords:
personalized targeted therapybiliary tract cancernon radical resectiontargeted deep sequencingprognosis

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K